{
    "nctId": "NCT04639219",
    "briefTitle": "A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations",
    "officialTitle": "A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 102,
    "primaryOutcomeMeasure": "Confirmed Overall Response Rate (ORR) as Per RECIST v1.1 Using Independent Central Review (ICR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adults \u226518 years old. Other age restrictions may apply as per local regulations.\n* Unresectable and/or metastatic solid tumors with pre-specified HER2 mutations (S310F, S310Y, G660D, R678Q, D769Y, D769H, V777L, Y772_A775dup / A775_G776insYVMA, L755S, G778_P780dup / P780_Y781insGSP, T862A, and V842I locally determined by NGS or a validated nucleic acid-based methodology (eg, qPCR, digital PCR) on tumor tissue, who have progressed following prior treatment or who have no satisfactory alternative treatment options.\n* Prior HER2 targeted therapy is permitted.\n* All patients must provide an FFPE tumor sample for retrospective central HER2 testing.\n* LVEF \u226550%\n* ECOG 0-1\n* All patients have measurable target disease assessed by the Investigator based on RECIST v1.1\n\nExclusion Criteria:\n\n* HER2 overexpressing (IHC3+ or IHC2+/ISH+) breast, gastric or gastroesophageal junction adenocarcinoma.\n* HER2 mutant NSCLC.\n* Medical history of myocardial infarction within 6 months before randomization/enrolment, symptomatic CHF, unstable angina pectoris, clinically important cardiac arrhythmias, or a recent (\\< 6 months) cardiovascular event including stroke.\n* History of non-infectious pneumonitis/ILD, current ILD, or where suspected ILD cannot be ruled out by imaging at screening\n* Corrected QT interval by Fridericia's formula (QTcF) prolongation to \\> 470 msec (females) or \\> 450 msec (males) based on average of the screening triplicate 12-lead ECG.\n* Lung-specific intercurrent clinically significant severe illnesses.\n* History of active primary immunodeficiency, known HIV, active HBV or HCV infection\n* Uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals\n* Pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy (CART).\n* Has spinal cord compression or clinically active central nervous system metastases.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}